- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04065230
Study of Tenofovir Alafenamide Fumarate Tablets (TAF) in Blocking Mother-to-child Transmission of Hepatitis B Virus
August 20, 2019 updated by: Guo-rong Han, Southeast University, China
A Prospective,Multi-center,Cohort Trial: the Efficacy and Safety of Tenofovir Alafenamide Fumarate Tablets (TAF) in Blocking Mother-to-child Transmission of Hepatitis B Virus(HBV)
This study is a single-group, multi-center and prospective clinical study designed to assess the efficacy and safety of TAF in blocking mother-to-child transmission of hepatitis B virus.Pregnant women whose HBsAg and HBeAg are positive are included in the study.Eligible hepatitis B pregnant women are given TAF antiviral therapy at 24-28 weeks of gestation to block mother-to-child transmission and followed up during pregnancy and after delivery.The study will be initiated with approval by the central ethics committee.Subjects will start screening after signing the informed consent form.
Those who meet the criteria will start taking TAF (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.At that time, chronic hepatitis B carrier will stop taking antiviral therapy, and patients with chronic hepatitis B decide whether to continue the therapy according to the patient's condition.The babies born are immunized according to the national standard immunization program,, that is, 100 IU of hepatitis B immunoglobulin (HBIG) and 10 μg/0.5 ml of hepatitis B vaccine are given within 12 hours after birth.
And the same dose of hepatitis B vaccine is given at 1 month and 6 months of age.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
330
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Guorong Han
- Phone Number: 13851623507
- Email: hgr518@163.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210003
- Recruiting
- The Affiliated Nanjing Hospital of Nanjing University of Chinese Medicine (The Second Hospital of Nanjing)
-
Contact:
- Guorong Han
- Phone Number: 13851623507
- Email: hgr518@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 35 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Probability Sample
Study Population
Pregnant women in the Affiliated Nanjing Hospital of Nanjing University of Chinese Medicine (The Second Hospital of Nanjing) whose HBsAg and HBeAg are positive are enrolled in the study.
TAF is used as antiviral therapy during 24-28 week of gestation.The safety and efficacy of TAF are evaluated.
Description
Inclusion Criteria:
- maternal age: 20 to 35 years
- 20-24 week of gestation
- HBsAg-positive more than 6 months and HBeAg-positive
- HBV DNA> 1000,000 IU/ml
- both husband and wife voluntarily sign informed consent
- with good compliance and comply with follow-up programs
Exclusion Criteria:
- mother with co-infection of hepatitis C virus,human immunodeficiency virus
- evidence of decompensated liver disease
- combined with important organ lesions which will affect patient compliance and follow-up plans, pregnant women who are expected to be difficult to complete the study
- have a history of spontaneous abortion, or have a birth defect or congenital malformation in the last pregnancy
- mother treated with antiviral therapy within 6 months prior to enrollment(except those treated with antiviral therapy in the last pregnancy to prevent mother-to-child transmission)
- have a history of kidney injury, creatinine clearance <50ml/min, urine protein positive (>300mg/L)
- combined with other chronic diseases and need to take immunomodulators, cytotoxic drugs or hormonal drugs during pregnancy
- the infants' biologic father is a chronic HBV infected person
- symptoms of threatened abortion during early pregnancy
- evidence of hepatic cell carcinoma
- alanine aminotransferase (ALT) > 10 x upper limit of normal(ULN ), or total bilirubin (TBIL) > 3 x ULN or glomerular filtration rate (GFR) < 90 mL (min*1.73 m2), or serum Albumin (ALB) < 25 g/L before enrollment
- fetal malformations detected by B-ultrasound
- participants in other research
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
TAF antiviral therapy group
|
Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MTCT rates in the TAF treated mothers
Time Frame: 28 weeks post-partum
|
detectable levels of HBV DNA or HBsAg in the peripheral serum samples of infants at age 28 weeks
|
28 weeks post-partum
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
August 1, 2019
Primary Completion (ANTICIPATED)
August 1, 2021
Study Completion (ANTICIPATED)
August 1, 2021
Study Registration Dates
First Submitted
August 18, 2019
First Submitted That Met QC Criteria
August 20, 2019
First Posted (ACTUAL)
August 22, 2019
Study Record Updates
Last Update Posted (ACTUAL)
August 22, 2019
Last Update Submitted That Met QC Criteria
August 20, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis B
- Hepatitis
- Hepatitis A
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
Other Study ID Numbers
- H201908
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B Virus
-
Enanta Pharmaceuticals, IncTerminatedChronic Hepatitis B Virus InfectionNew Zealand
-
Ain Shams UniversityCompleted
-
Tasly Tianjin Biopharmaceutical Co., Ltd.Unknown
-
Bristol-Myers SquibbCompletedChronic Hepatitis B Virus, PediatricUnited States, Korea, Republic of, Taiwan, United Kingdom, Belgium, Canada, Russian Federation, Argentina, Germany, Greece, India, Israel, Poland, Romania
-
Yangshengtang Co., LtdNot yet recruitingChronic Hepatitis B Virus Infection
-
Tasly Tianjin Biopharmaceutical Co., Ltd.CompletedHepatitis B Virus (HBV)China
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Hoffmann-La RocheTerminatedHepatitis B Virus InfectionUnited Kingdom, Hong Kong, Korea, Republic of, Taiwan, Poland, Bulgaria, New Zealand
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bMoldova, Republic of, Ukraine
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruiting
Clinical Trials on Tenofovir Alafenamide Fumarate tablets
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.The First Hospital of Jilin UniversityRecruitingPharmacokinetics | Efficacy | SafetyChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Jiangsu Aidea Pharmaceutical Co., LtdChengdu Aidea Pharmaceutical Technology Co., LtdRecruitingHealthy Adult ParticipantsChina
-
Mahidol UniversityRecruitingRenal Insufficiency | TenofovirThailand
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingHIV InfectionsUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis BChina
-
University of California, San DiegoGilead Sciences; University at BuffaloCompleted
-
Eastern Virginia Medical SchoolGilead Sciences; United States Agency for International Development (USAID); FHI... and other collaboratorsActive, not recruitingAdherence, Medication | Acceptability of Health CareSouth Africa, Zimbabwe
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingChronic Hepatitis b | Cirrhosis Due to Hepatitis BChina
-
ANRS, Emerging Infectious DiseasesGilead Sciences; Ministry of Health, Thailand; Assistance Publique - Hôpitaux... and other collaboratorsNot yet recruiting